Browse

The Role of Whole-Body FDG PET/CT, Tc 99m MDP Bone Scintigraphy, and Serum Alkaline Phosphatase in Detecting Bone Metastasis in Patients with Newly Diagnosed Lung Cancer

DC Field Value Language
dc.contributor.authorMin, Joo-Won-
dc.contributor.authorUm, Sang-Won-
dc.contributor.authorYim, Jae-Jun-
dc.contributor.authorYoo, Chul-Gyu-
dc.contributor.authorShim, Young-Soo-
dc.contributor.authorKim, Young Whan-
dc.contributor.authorHan, Sung Koo-
dc.date.accessioned2012-05-23T06:55:44Z-
dc.date.available2012-05-23T06:55:44Z-
dc.date.issued2009-04-
dc.identifier.citationJOURNAL OF KOREAN MEDICAL SCIENCE; Vol.24 2; 275-280ko_KR
dc.identifier.issn1011-8934-
dc.identifier.urihttp://hdl.handle.net/10371/76334-
dc.description.abstractBone scan (BS) and serum alkaline phosphatase (ALP) concentration are used to detect bone metastasis in malignancy, although whole-body fluoro-D-glucose positron emission tomography computed tomography (FDG PET/CT) is being used increasingly. But BS is still used for the detection of metastatic bone lesion. So we compared the usefulness of PET/CT, BS, and serum ALP in detecting bone metastases in patients with newly diagnosed lung cancer. The medical record database was queried to identify all patients with a new diagnosis of lung cancer between January 2004 and December 2005, who had a PET/CT, BS, and serum ALP before treatment. We retrospectively reviewed all patients` records and radiological reports. One hundred eighty-two patients met the inclusion criteria. Bone metastases were confirmed in 30 patients. The sensitivity values were 93.3% for PET/CT, 93.3% for BS, 26.7% for serum ALP concentration, and 26.7% for BS complemented with serum ALP concentration. The respective specificity values were 94.1%, 44.1%, 94.1%, and 97.3%. The kappa statistic suggested a poor agreement among the three modalities. FDG PET/CT and BS had similar sensitivity, but PET/CT had better specificity and accuracy than BS. PET/CT is more useful than BS for evaluating bone metastasis. However, in the advanced stage, because of its high specificity, BS complemented with serum ALP is a cost-effective modality to avoid having to use PET/CT.ko_KR
dc.language.isoenko_KR
dc.publisherKOREAN ACAD MEDICAL SCIENCESko_KR
dc.subjectLung Neoplasmsko_KR
dc.subjectAlkaline Phosphataseko_KR
dc.subjectBone Scanko_KR
dc.subjectBone Metastasisko_KR
dc.subjectFluorodeoxyglucose F18ko_KR
dc.subjectPET/CTko_KR
dc.titleThe Role of Whole-Body FDG PET/CT, Tc 99m MDP Bone Scintigraphy, and Serum Alkaline Phosphatase in Detecting Bone Metastasis in Patients with Newly Diagnosed Lung Cancerko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor민주원-
dc.contributor.AlternativeAuthor엄상원-
dc.contributor.AlternativeAuthor임재준-
dc.contributor.AlternativeAuthor유철규-
dc.contributor.AlternativeAuthor한성구-
dc.contributor.AlternativeAuthor심영수-
dc.contributor.AlternativeAuthor김영환-
dc.identifier.doi10.3346/jkms.2009.24.2.275-
dc.citation.journaltitleJOURNAL OF KOREAN MEDICAL SCIENCE-
dc.description.citedreferenceEven-Sapir E, 2006, J NUCL MED, V47, P287-
dc.description.citedreferenceLiu FY, 2006, J CLIN ONCOL, V24, P599, DOI 10.1200/JCO.2005.03.8760-
dc.description.citedreferenceAbe K, 2005, ANN NUCL MED, V19, P573-
dc.description.citedreferenceChung JH, 2005, YONSEI MED J, V46, P388-
dc.description.citedreferenceErturan S, 2005, CHEST, V127, P449-
dc.description.citedreferenceEbert W, 2004, ANTICANCER RES, V24, P3193-
dc.description.citedreferenceCheran SK, 2004, LUNG CANCER-J IASLC, V44, P317, DOI 10.1016/j.lungcan.2003.11.008-
dc.description.citedreferenceEven-Sapir E, 2004, J NUCL MED, V45, P272-
dc.description.citedreferencePeterson JJ, 2003, CLIN ORTHOP RELAT R, pS120, DOI 10.1097/01.blo.0000093051.96273.7c-
dc.description.citedreferenceBar-Shalom R, 2003, J NUCL MED, V44, P1200-
dc.description.citedreferenceToloza EM, 2003, CHEST, V123, p137S-
dc.description.citedreferenceHany TF, 2002, RADIOLOGY, V225, P575, DOI 10.1148/radiol.2252011568-
dc.description.citedreferenceYang SN, 2002, J CANCER RES CLIN, V128, P325, DOI 10.1007/s00432-002-0342-5-
dc.description.citedreferenceAlatas F, 2002, CLIN BIOCHEM, V35, P293-
dc.description.citedreferenceSchirrmeister H, 2001, J NUCL MED, V42, P1800-
dc.description.citedreferenceOhta M, 2001, NUCL MED COMMUN, V22, P875-
dc.description.citedreferenceCook GJR, 2001, Q J NUCL MED, V45, P47-
dc.description.citedreferenceCook GJ, 1998, J CLIN ONCOL, V16, P3375-
dc.description.citedreferenceHoegerle S, 1998, RADIOLOGY, V209, P253-
dc.description.citedreferenceBury T, 1998, EUR J NUCL MED, V25, P1244-
dc.description.citedreferenceAruga A, 1997, BRIT J CANCER, V76, P760-
dc.description.citedreferenceShreve PD, 1996, RADIOLOGY, V199, P751-
dc.description.citedreferenceTRITZ DB, 1989, CANCER, V63, P763-
dc.description.tc10-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse